Neil Desai, PhD
Founder, CEO and President
Neil is the Founder of Aadi Bioscience, Inc. He was former SVP, Global R&D, Abraxis Bioscience; VP, Strategic Platforms, Celgene Corp; Inventor of the nab® technology, Abraxane® and ABI-009. He successfully led the Abraxane team through all development stages. He has over 25 years of experience in novel therapeutic delivery systems with over 100 issued patents, over 40 peer-reviewed publications and book chapters, and over 200 presentations at scientific meetings. He is an active participant in FDA and EU Nanotechnology initiatives and a member of the Steering Committee for the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer. He holds board and advisory positions in various start-ups. He holds a M.S and Ph.D. in Chemical Engineering from the University of Texas at Austin, USA, and a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.
Mitchall Clark, Bpharm, MRPharmS
Regulatory Affairs and Quality Advisor
SVP, Regulatory Affairs and Quality Assurance
Mitch is was formerly Chief Regulatory /Quality, Atara Biotherapeutics, ; he was formerly SVP Regulatory Affairs, Nantworks, and SVP Regulatory affairs at Abraxis Bioscience where he was responsible for global approvals for Abraxane® and regulatory for early stage to post-marketing of nab products. He has 30+ yrs in international regulatory affairs with Schering AG, FH Faulding/Purepac & APP/Abraxis, Clinical and Manufacturing QA, drug safety and clinical operations.
Berta Grigorian, BS
VP, Clinical Operations
Berta was former Clinical Operations Manager, Amgen Inc. with 20 years industry experience in all phases of drug development, Oncology and Cardiovascular products. She led cross functional teams management to plan and execute a successful US BLA filing for an Amgen cardiovascular product, she has led global activities for various oncology studies to ensure quality, consistency, and integration of all study data, and she was responsible for global study management goals (enrollment, data flow, drug supply) for several clinical products.